Incyte Announces Topline Results From Study Of Tafasitamab Met Its Primary Endpoint Of Progression Free Survival In Relapsed Or Refractory Follicular Lymphoma; The Secondary Endpoint Of PFS Results By Blinded Independent Review Are Consistent With Investigator Based PFS Results. No New Safety Signals With Tafasitamab Were Observed
Portfolio Pulse from Benzinga Newsdesk
Incyte (NASDAQ:INCY) announced positive topline results from its Phase 3 inMIND trial for tafasitamab (Monjuvi®) in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma (FL). The trial met its primary endpoint of progression free survival (PFS) and key secondary endpoints. No new safety signals were observed. Incyte plans to file a supplemental Biologics License Application by the end of the year.
August 15, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Incyte's Phase 3 inMIND trial for tafasitamab (Monjuvi®) in combination with lenalidomide and rituximab met its primary and key secondary endpoints in relapsed or refractory follicular lymphoma. No new safety signals were observed. Incyte plans to file a supplemental Biologics License Application by the end of the year.
The positive results from the Phase 3 trial and the plan to file a supplemental Biologics License Application are likely to boost investor confidence and positively impact Incyte's stock price in the short term. Meeting primary and key secondary endpoints without new safety signals is a significant milestone.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100